HC Wainwright Has Negative Estimate for CareDx Q1 Earnings

CareDx, Inc (NASDAQ:CDNA) – Equities research analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for CareDx in a research note issued on Monday, March 3rd. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.21) per share for the quarter, down from their previous estimate of ($0.12). HC Wainwright has a “Neutral” rating and a $25.00 price target on the stock. The consensus estimate for CareDx’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for CareDx’s Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.50) EPS.

CareDx (NASDAQ:CDNA) last issued its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business had revenue of $86.58 million for the quarter, compared to analysts’ expectations of $84.56 million.

Other research analysts have also recently issued research reports about the stock. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a report on Wednesday, February 26th. Stephens reaffirmed an “overweight” rating and issued a $40.00 price target on shares of CareDx in a report on Thursday, February 27th. Finally, Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and decreased their price target for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.83.

CareDx Stock Performance

CareDx stock opened at $18.90 on Thursday. The stock has a market cap of $1.01 billion, a P/E ratio of -7.00 and a beta of 1.87. CareDx has a fifty-two week low of $7.42 and a fifty-two week high of $34.84. The firm’s fifty day moving average price is $22.65 and its 200-day moving average price is $25.02.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp bought a new position in CareDx in the fourth quarter valued at $631,000. Public Employees Retirement System of Ohio increased its stake in CareDx by 6.5% in the fourth quarter. Public Employees Retirement System of Ohio now owns 53,672 shares of the company’s stock valued at $1,149,000 after acquiring an additional 3,287 shares during the last quarter. Castleark Management LLC increased its stake in CareDx by 41.7% in the fourth quarter. Castleark Management LLC now owns 198,180 shares of the company’s stock valued at $4,243,000 after acquiring an additional 58,300 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in CareDx by 124.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 120,347 shares of the company’s stock valued at $2,577,000 after acquiring an additional 66,833 shares during the last quarter. Finally, Squarepoint Ops LLC increased its stake in CareDx by 7.7% in the fourth quarter. Squarepoint Ops LLC now owns 231,235 shares of the company’s stock valued at $4,951,000 after acquiring an additional 16,484 shares during the last quarter.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.